EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model

Myung-Hwan KIM; Heung-Moon CHANG; Tae-Won KIM; Sung-Koo LEE; Jung-Sun PARK; Young-Hoon KIM; Tae-Yoon LEE; Se-Jin JANG; Chul-Won SUH; Tae-Suk LEE; Sang-Hee KIM; Sung-Gyu LEE.
Journal of Korean Medical Science ; : 474-480, 2009.
Artículo en Inglés | WPRIM | ID: wpr-134346

Documentos relacionados

  1. EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model.
  2. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
  3. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
  4. Emerging molecular target antagonists for the treatment of biliary tract cancer.
  5. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
  6. Rational development of combination therapies for biliary tract cancers.
  7. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
  8. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
  9. Second-line chemotherapy in advanced biliary cancer: a systematic review.
  10. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.